5,6-dihydro-2H-pyran-2,4-dione | 33532-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 5,6-dihydro-2H-pyran-2,4-dione
• 英文别名: β-keto-δ-valerolactone；dihydro-2H-pyran-2,4(3H)-dione；5,6-dihydro-2,4(3H)-dione；4-oxotetrahydropyranone；dihydropyran-2,4-dione；3-Oxopentan-5-olide；oxane-2,4-dione
• CAS: 33532-46-6
• 化学式: C₅H₆O₃
• 分子量: 114.101
• InChiKey: CNRPRLWCUGZYJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-dihydro-2H-pyran-2,4-dione 在 吡啶 、 pyridinium hydrobromide perbromide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 84.0h， 生成 8-(3-Bromo-4-fluorophenyl)-5,11-dioxa-2-azatricyclo[7.4.0.03,7]trideca-1(9),3(7)-diene-6,10-dione
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of a Novel Series of Tricyclic Dihydropyridine-Based K_ATP Openers That Potently Inhibit Bladder Contractions in Vitro

  摘要：

  Structure-activity relationships were investigated on a novel series of tricyclic dihydropyridine-containing K-ATP openers. This diverse group of analogues, comprising a variety of heterocyclic rings fused to the dihydropyridine nucleus, was designed to determine the influence on activity of hydrogen-bond-donating and -accepting groups and their stereochemical disposition. Compounds were evaluated for K-ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a subset of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation.

  DOI：

  10.1021/jm030357o
• 作为产物：
  描述：

  4-羟基吡喃-2-酮 生成 5,6-dihydro-2H-pyran-2,4-dione
  参考文献：
  名称：

  KODZIMA, SIGEHRU;OKABEH, TAKASI;OISI, XARUXITO;TANINAKA, CATOPY

  摘要：

  DOI：

文献信息

• Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
  申请人：——

  公开号：US20020007059A1

  公开（公告）日：2002-01-17

  Compounds of formula I 1 are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

  公式I的化合物在治疗由钾通道开放剂预防或改善的疾病中很有用。还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• Dihydronaphthyridine potassium channel openers
  申请人：——

  公开号：US20020099070A1

  公开（公告）日：2002-07-25

  Compounds of formula I 1 are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

  化合物I1的公式在治疗由钾通道开放剂预防或改善的疾病中很有用。还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
• β-Keto -δ-valerolactone: synthesis and use as methylvinylketone anion equivalent in michael additions
  作者：Jean d'Angelo、Domingo Gomez-Pardo

  DOI：10.1016/0040-4039(91)80689-4

  日期：1991.6

  β-Keto-δ-valerolactone 11 was prepared from 3-butyn-l-ol 6 in 5 steps (50 % overall yield). This lactone was added to Michael acceptors 13, 17, 19 and 25, giving adducts 14, 18, 20 and 26 respectively.

  β-酮-δ-戊内酯11由3-丁炔-1-醇6分5步制备（总收率50％）。此内酯加入到迈克尔受体13，17，19和25，使加合物14，18，20和26分别。
• Preparation of Hexahydrobenzo[<i>f</i>]isoquinolines Using a Vinylogous Pictet−Spengler Cyclization
  作者：Richard R. Cesati、John A. Katzenellenbogen

  DOI：10.1021/ol006533u

  日期：2000.11.1

  A vinylogous Pictet-Spengler cyclization has been carried out using activated aldehydes, ketones, and alkynes to prepare a variety of substituted hexahydrobenzo[f]isoquinolines. A unique set of conditions was utilized to effect efficient cyclization with acid-sensitive electrophiles.

  使用活化的醛，酮和炔进行了乙烯基的Pictet-Spengler环化反应，以制备各种取代的六氢苯并[f]异喹啉。利用一组独特的条件来实现对酸敏感的亲电试剂的有效环化。